SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-20-121018
Filing Date
2020-04-27
Accepted
2020-04-27 16:32:32
Documents
6
Effectiveness Date
2020-04-27

Document Format Files

Seq Description Document Type Size
1 DEFA14A d880266ddefa14a.htm DEFA14A 38512
2 GRAPHIC g880266na1a.jpg GRAPHIC 1344
3 GRAPHIC g880266na1b.jpg GRAPHIC 2560
4 GRAPHIC g880266na2.jpg GRAPHIC 1326
5 GRAPHIC g880266na3.jpg GRAPHIC 1331
6 GRAPHIC g880266na4.jpg GRAPHIC 1342
  Complete submission text file 0001193125-20-121018.txt   51123
Mailing Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016
Business Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016 917-336-9310
Prevail Therapeutics Inc. (Filer) CIK: 0001714798 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38939 | Film No.: 20820512
SIC: 2836 Biological Products, (No Diagnostic Substances)